Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GDRX
GDRX logo

GDRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy GoodRx Holdings Inc (GDRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.660
1 Day change
1.92%
52 Week Range
5.810
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

GoodRx Holdings Inc (GDRX) does not currently present a strong buy opportunity for a long-term beginner investor. While analysts have raised price targets and maintained buy ratings, the technical indicators are bearish, hedge funds are selling, and there is no recent positive news or financial data to support a strong upward trend. The options data suggests a bullish sentiment with low put-call ratios, but this alone is insufficient to recommend a buy given the broader context.

Technical Analysis

The technical indicators for GDRX are bearish. The MACD histogram is negative and contracting, RSI is neutral at 46.447, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 2.667, with resistance at 2.816 and support at 2.518.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
5

Positive Catalysts

  • Analysts have raised price targets recently, with Citi and TD Cowen maintaining buy ratings. The options data shows a bullish sentiment with a low put-call ratio.

Neutral/Negative Catalysts

  • Hedge funds are selling heavily, with a 1160% increase in selling activity over the last quarter. Technical indicators are bearish, and there is no recent news or financial data to support a strong upward trend.

Financial Performance

No financial data or valuation information is available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have raised price targets recently: Citi to $4 from $3.50, TD Cowen to $4 from $3, and Goldman Sachs to $3.50 from $2.50. Citi and TD Cowen maintain buy ratings, while Goldman Sachs remains neutral.

Wall Street analysts forecast GDRX stock price to rise
10 Analyst Rating
Wall Street analysts forecast GDRX stock price to rise
4 Buy
4 Hold
2 Sell
Hold
Current: 2.610
sliders
Low
2.6
Averages
4.46
High
7
Current: 2.610
sliders
Low
2.6
Averages
4.46
High
7
Citi
Buy
upgrade
$4
AI Analysis
2026-05-14
Reason
Citi
Price Target
$4
AI Analysis
2026-05-14
upgrade
Buy
Reason
Citi raised the firm's price target on GoodRx to $4 from $3.50 and keeps a Buy rating on the shares.
TD Cowen
Charles Rhyee
Buy
maintain
$3 -> $4
2026-05-11
Reason
TD Cowen
Charles Rhyee
Price Target
$3 -> $4
2026-05-11
maintain
Buy
Reason
TD Cowen analyst Charles Rhyee raised the firm's price target on GoodRx to $4 from $3 and keeps a Buy rating on the shares. The firm said the company showed an encouraging quarter, with Pharma Direct driving a consolidated beat/raise on revenues and EBITDA.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GDRX
Unlock Now

People Also Watch